High triglycerides drive life threatening aortic aneurysms, study in mice finds

A drug candidate significantly reduced aortic aneurysm development, showing promise of triglyceride-lowering therapy as a treatment target

5:00 AM

Author | Noah Fromson

microscope drawing in navy and yellow with off white background
Justine Ross, Jacob Dwyer, Michigan Medicine

High levels of triglycerides, the most common type of fat in the body and the foods we eat, directly cause abdominal aortic aneurysms, according to a study in mouse models led by Michigan Medicine.

Researchers identified triglyceride-rich lipoproteins and proteins that regulate triglyceride metabolism, including APOC3 and ANGPTL3, as causal drivers of abdominal aortic aneurysm.

The study challenges the long-standing belief that triglycerides are merely biomarkers of vascular disease and instead demonstrates that they play a direct and pathogenic role in aneurysm development, growth and rupture.

The results are published in Circulation, a journal of the American Heart Association.

“We have known that hyperlipidemia is a risk factor for aortic aneurysm, but this multidimensional study pinpoints hypertriglyceridemia as an essential contributor to the development and growth, as well as dissection and rupture, of aortic aneurysms,” said co-senior author Eugene Chen, M.D., Ph.D., Frederick G. L. Huetwell Professor of Cardiovascular Medicine at University of Michigan Medical School.

“Our findings suggest that managing triglycerides could become a powerful therapeutic strategy.”

Using three different mouse models of hypertriglyceridemia, the research team demonstrated a triglyceride dose-dependent effect on aneurysm severity.

Moderate elevations in triglycerides accelerated aneurysm formation, while higher levels led to aortic dissection.

Mice with severely elevated triglyceride concentrations developed more severe complications consistent with aortic rupture.

Further investigation revealed that elevated triglycerides and related fatty acids, particularly palmitate, impaired the maturation and activity of lysyl oxidase, a critical enzyme that maintains the structural integrity of the aortic wall.

This enzyme dysfunction weakened connective tissue and promoted aneurysm progression.

By overexpressing LOX in the aorta, researchers effectively blocked the damaging effects of hypertriglyceridemia in the mouse models, confirming the mechanism.

Standard lipid-lowering therapies, such as niacin, didn't sufficiently reduce triglyceride levels to a protective range.

However, investigators found success with experimental antisense oligonucleotide therapy.

The drug candidate targets the ANGPTL3, which is secreted in the liver and affects how the body breaks down fats.

The treatment dramatically lowered triglyceride levels by up to 50% and prevented aneurysm formation and dissection in multiple mouse models.

“This therapy holds great potential as a treatment for abdominal aortic aneurysm, and our research lays the groundwork for future clinical trials,” said co-senior author Yanhong Guo, M.D., Ph.D., research assistant professor of internal medicine at U-M Medical School and member of the U-M Health Frankel Cardiovascular Center.

“This is an exciting development for a condition that currently has limited options beyond surgical repair. The findings may represent a paradigm shift in how vascular diseases like abdominal aortic aneurysm are understood and treated, offering hope for patients at high risk who currently lack effective pharmacological interventions.”

Additional authors: Yaozhong Liu, M.D., Minzhi Yu, Ph.D., Ying Zhao, Yalun Cheng, M.D., Yongjie Deng, M.D., Yang Zhao, Ph.D., Xiaokang Wu, M.D., Ph.D., Huilun Wang, Ph.D., Guizhen Zhao, Ph.D., Chao Xue, M.D., Ph.D., Hongyu Liu, M.D., Ida Surakka, Ph.D., Anna Schwendeman, Ph.D., Lin Chang, Ph.D., Jifeng Zhang, Ph.D., all of University of Michigan, Lei Cai, Ph.D., Hong S. Lu, Ph.D., Alan Daugherty, Ph.D., Ryan E. Temel, Ph.D., all of Saha Cardiovascular Research Center and the Department of Physiology at University of Kentucky, Haocheng Lu, Ph.D., of Southern University of Science and Technology.

Funding/disclosures: This study was partially supported by the National Heart, Lung, and Blood Institute (HL166203, HL165688, HL109946, HL134569, HL151524, HL153710, HL172832, HL155649) and the National Center for Advancing Translational Sciences (UL1TR001998) of the National Institutes of Health.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

The study also received partial support from the American Heart Association.

Paper cited: “Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models,” Circulation. DOI: 10.1161/CIRCULATIONAHA.125.074737


More Articles About:

Cardiovascular: Diseases & Conditions Aortic Disease Aortic Aneurysm Basic Science and Laboratory Research Cardiovascular: Treatment & Surgery
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story

portrait of Yanhong Guo

Yanhong Guo

Research Associate Professor

Yuqing Chen headshot

Yuqing E Chen

Professor

Related

blood vessel up close with red cells and yellow inside
Health Lab

Drug candidate successfully treats atherosclerosis, fatty liver disease in large mammals 

A compound that was previously found to treat severe fatty liver disease also reduces atherosclerosis, a primary driver of cardiovascular death, in non-human primates. The drug candidate was developed at the University of Michigan.
doctors in surgery room over surgery table with cooler open with labels on it
Health Lab

Why donor hearts fail in cold storage — and how to prevent it

Researchers have discovered a new molecular process that occurs when donor hearts are preserved in cold storage which contributes to failure after transplant, a study in both humans and animals shows. Fortunately, therapy that is typically prescribed for high blood pressure can target this process to reduce cold preservation associated with cardiac injury. This discovery has potential to improve the consistent function of donor hearts and extend the distance they can be safely transported in cold storage.

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Two people in medical scrubs are in a blurred hospital setting. In the foreground, hands are holding a digital tablet.
Health Lab

Digital alerts support timely treatment decisions of critically ill cardiac patients

Well-designed alerts for critically ill cardiac patients can change what happens at the bedside, according to new Michigan Medicine research.
Father comforts sick child
News Release

15 years of data will help uncover how flu spreads—and how to reduce its impact

$14.2-million NIH award to University of Michigan funds research to untangle intricacies of person-to-person flu transmission—and reduce illness, deaths, economic losses
Michelle Hastings, Ph.D. and lab member look at molecule on computer screen.
News Release

$3.9 million NIH grant to fuel U-M effort to develop first targeted therapy for fatal childhood brain disorder

A team led by Dr. Michelle Hastings will advance a new RNA-based medicine for the most common form of CLN3 Batten disease toward clinical trials
A stylized digital image of an X-ray of a human skeleton superimposed on a strand of DNA
Health Lab

Bigger data reveals the second, third and fourth switches controlling a gene

A University of Michigan study reveals the untapped potential of the NIH-sponsored Trans-Omics for Precision Medicine, or TOPMed, program.
layers of skin pink to yellow
Health Lab

Study outlines a new framework for direct cell reprogramming

In a new paper published in the journal iScience, Lindsey Muir, Ph.D. and her lab at Michigan Medicine propose a framework for direct cell reprogramming.
Minding memory above a microphone on a blue background
Minding Memory

Is the United States Lagging Behind Europe in Memory Improvement?

In this episode, Lauren & Matt speak with Neil Mehta, PhD who is the associate dean for research and a professor in the Department of Epidemiology at the University of Texas Medical Branch in Galveston. Dr. Mehta’s research focuses on US life expectancy trends, the effects of obesity on disability and mortality, the sources of socioeconomic status disparities in mortality, and patterns of health in the United States and Europe. Dr. Mehta talks about a recent manuscript from the NIA-funded TRENDS study called “Trends in Memory Function and Memory Impairment Among Older Adults in the United States and Europe, 1996 to 2018.”, which looks at data from several sources to compare trends in memory function across 13 different countries.